AstraZeneca: Amgen leaves AstraZeneca alone with brodalumabNEUTRAL, Fair Value 4830p vs. 4860p (+8%)
Amgen has decided to terminate the agreement on brodalumab because suicidal ideation should negatively impact the label of the drug. AstraZeneca now has to decide what to do with it. We are cutting by half the PoS of brodalumab in our model to 30%, reducing the FV to 4,830p.
For more information, please contact email@example.com